Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NEU2 | Q9Y3R4 | 5/20 | 0.34 |
| ▸ | NEU1 | Q99519 | 5/20 | 0.33 |
| ▸ | NANP | Q8TBE9 | 2/20 | 0.33 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.33 |
| ▸ | NEU4 | Q8WWR8 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022488 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL15962573 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL15250603 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL18333556 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL18934165 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL18463646 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL16869870 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL15250602 | 1.00 | L3MBTL1 (0.50) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL22022487 | 0.86 | L3MBTL1 (0.52) | L3MBTL1NEU2NEU1NANPNEU3 | |
| SCHEMBL18463735 | 0.86 | L3MBTL1 (0.52) | L3MBTL1NEU2NEU1NANPNEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289721-A1 | DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | GLYCOM A/S (DK) | 2016-10-06 | — | — | US | disclosed |
| US-9382564-B2 | Diversification of human milk oligosaccharides (HMOs) or precursors thereof | GLYCOM A/S (DK) | 2016-07-05 | — | — | US | disclosed |
| US-20160113952-A1 | Synthetic Mixture of Oligosaccharides for Treating a Microbiota of a Mammal | GLYCOM A/S (DK) | 2016-04-28 | — | — | US | disclosed |
| US-9102966-B2 | Synthesis of sialooligosaccharide derivatives | GLYCOM A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| US-20140212930-A1 | DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF | GLYCOM A/S (DK) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113952-A1 | Synthetic Mixture of Oligosaccharides for Treating a Microbiota of a Mammal | FUT5, FUT6, FUCA1 | L3MBTL1 646/4885NEU2 39/4885NEU1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.